Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.

[1]  S. Rajkumar,et al.  Dermatologic side effects of thalidomide in patients with multiple myeloma. , 2003, Journal of the American Academy of Dermatology.

[2]  S. Gillessen,et al.  Thalidomide: from tragedy to promise. , 2003, Swiss medical weekly.

[3]  P. Bouche,et al.  Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. , 2002, The Journal of investigative dermatology.

[4]  F. Kontopidou,et al.  Thalidomide in the treatment of myelodysplastic syndrome with fibrosis. , 2002, Leukemia research.

[5]  M. Baccarani,et al.  Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. , 2002, Blood.

[6]  B. Barlogie,et al.  Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.

[7]  I. Yakoub-Agha,et al.  Efficacy of a low dose of thalidomide in advanced multiple myeloma. , 2002, Blood.

[8]  J. English,et al.  Diffuse cutaneous mucinoses. , 2002, Dermatologic clinics.

[9]  Hannes Kaufmann,et al.  Thromboembolic events during treatment with thalidomide. , 2002, Blood.

[10]  S. Rajkumar,et al.  Deep venous thrombosis and thalidomide therapy for multiple myeloma. , 2001, The New England journal of medicine.

[11]  A. Rebora,et al.  Cutaneous Mucinoses: Microscopic Criteria for Diagnosis , 2001, The American Journal of dermatopathology.

[12]  A. Rebora,et al.  Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. , 2001, Journal of the American Academy of Dermatology.

[13]  I. Forgacs,et al.  Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). , 2000, Journal of the American Academy of Dermatology.

[14]  E. Bisaccia,et al.  Scleromyxedema with dermato-neuro syndrome. , 2000, Journal of the American Academy of Dermatology.

[15]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[16]  A. Pandya,et al.  Fatal scleromyxedema: report of a case and review of the literature. , 1998, Journal of the American Academy of Dermatology.

[17]  C M Lockwood,et al.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.

[18]  E. Atra,et al.  Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. , 1993, Clinical and experimental rheumatology.

[19]  P. Richardson,et al.  Thalidomide: emerging role in cancer medicine. , 2002, Annual review of medicine.

[20]  Black Mm,et al.  The dermal mucinoses. , 1993 .